Apoptosis in Health and Disease - Part A

Rossen Donev (Redaktør)

Apoptosis, or programmed cell death, is the mechanism by which cells die either physiologically or pathologically. A vast research in apoptosis has advanced our understanding of basic physiological and pathological processes occurring in cells, organs and organisms, and its role in a number of diseases. Les mer
Vår pris
2009,-

(Innbundet) Fri frakt!
Leveringstid: Sendes innen 21 dager

Innbundet
Legg i
Innbundet
Legg i
Vår pris: 2009,-

(Innbundet) Fri frakt!
Leveringstid: Sendes innen 21 dager

Om boka

Apoptosis, or programmed cell death, is the mechanism by which cells die either physiologically or pathologically. A vast research in apoptosis has advanced our understanding of basic physiological and pathological processes occurring in cells, organs and organisms, and its role in a number of diseases. These new advanced understandings are playing a major influence in drug discovery and the introduction of new therapies that target this cell death process. These two thematic volumes 125 and 126 of the Advances in Protein Chemistry and Structural Biology focus on apoptotic responses in numerous conditions - from bacterial and parasite infections to pathological states such as oxidative stress, pulmonary hypertension, different cancer types, etc. Finally, therapeutic strategies for targeting apoptosis are also discussed.

Fakta

Innholdsfortegnelse

1. Apoptosis in infectious diseases as a mechanism of immune evasion and survival
Jorge Quarleri, Cintia Cevallos, and Maria Victoria Delpino
2. Reactive oxygen mediated apoptosis as a therapeutic approach against opportunistic Candida albicans
Tanu Atriwal, Meenal Chawla, Afzal Hussain, Mohamed F. Alajmi, and Mohammad Abid
3. TRPM2 channel in oxidative stress-induced mitochondrial dysfunction and apoptotic cell death
Philippa Malko, Ran Ding, and Lin-Hua Jiang
4. Intrinsic and extrinsic pathways of apoptosis: Role in cancer development and prognosis
Dharambir Kashyap, Vivek Kumar Garg, and Neelam Goel
5. Immunological and functional aspects of MAGEA3 cancer/testis antigen
Biswajit Das and Shantibhusan Senapati
6. Role of histone acetyltransferase inhibitors in cancer therapy
Muthu K. Shanmugam, Arunasalam Dharmarajan, Sudha Warrier, Anupam Bishayee, Alan Prem Kumar, Gautam Sethi, and Kwang Seok Ahn
7. Triggering the downstream apoptotic signal inside human parasitic organisms demonstrates a promising approach for anti-parasitic drug development: A mechanistic perspective
Nikhilesh Joardar, Niladri Mukherjee, Satyajit Halder, Kuladip Jana, and Santi P. Sinha Babu
8. Ferulic acid-mediated modulation of apoptotic signaling pathways in cancer
Ashutosh Gupta, Amit Kumar Singh, Mariam Loka, Abhay Kumar Pandey, and Anupam Bishayee
9. S1PR1 signaling in cancer: A current perspective
B. Anu, N.N. Namitha, and K.B. Harikumar
10. Phyto-drug conjugated nanomaterials enhance apoptotic activity in cancer
Karuppaiya Vimala and Soundarapandian Kannan

Om forfatteren

Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.